论文部分内容阅读
目的观察重组人粒细胞刺激因子防治急性放射性黏膜炎的疗效。方法回顾性分析30例重组人粒细胞刺激因子治疗急性放射性黏膜炎患者,并随机抽取同期未予重组人粒细胞刺激因子治疗的30例急性放射性黏膜炎患者作为对照组。对照组:生理盐水80 ml+地塞米松5 mg+庆大霉素8万u+利多卡因400 mg(三餐后+睡前)每次20ml含漱。观察组:对照组基础上予生理盐水80 ml+欣粒生300μg。观察重组人粒细胞刺激因子治疗后急性放射性黏膜炎疗效及转归。结果观察组放射性黏膜炎发生率明显低于对照组,秩和检验显示,在放疗结束时,观察组3,4级放射性粘膜炎分级明显低于对照组,具有统计学差异(P<0.05)。口腔、咽部疼痛观察组明显低于对照组,放疗第35天,放疗结束时具有统计学差异(P<0.05)。结论重组人粒细胞刺激因子能推迟头颈部肿瘤患者放射性口腔炎的发生时间,降低3,4级放射性黏膜炎的发生率,并能促进放射性黏膜炎的愈合,缓解患者口咽疼痛。
Objective To observe the effect of recombinant human granulocyte stimulating factor in the prevention and treatment of acute radiation mucositis. Methods Thirty patients with acute radiation mucositis were treated with recombinant human granulocyte-stimulating factor. 30 patients with acute radiation mucositis who were not treated with recombinant human granulocyte-stimulating factor were randomly selected as the control group. Control group: saline 80 ml + dexamethasone 5 mg + gentamicin 80,000 u + lidocaine 400 mg (after meals + before going to bed) every time 20ml rinse. Observation group: the control group on the basis of saline 80 ml + Xin tablets students 300μg. To observe the efficacy and prognosis of acute radiation mucositis after treatment of recombinant human granulocyte-stimulating factor. Results The incidence of radiation mucositis in the observation group was significantly lower than that in the control group. The rank sum test showed that at the end of radiotherapy, the grading of radiosensitis in groups 3 and 4 was significantly lower than that in the control group (P <0.05). Oral and pharyngeal pain observation group was significantly lower than the control group, the first 35 days of radiotherapy, the end of radiotherapy with a statistically significant difference (P <0.05). Conclusion Recombinant human granulocyte-stimulating factor can delay the incidence of radiation stomatitis in patients with head and neck cancer, reduce the incidence of grade 3 and 4 radiation mucositis, promote the healing of radiation mucositis and ease the pain in patients with oropharyngeal pain.